Fasciolopsiasis, a food-borne trematode infection induced by the intestinal fluke Fasciolopsis buski, poses a significant health concern. Here at Protheragen, our unwavering dedication lies in spearheading the battle against fasciolopsiasis. We offer an all-encompassing range of services dedicated to the development of vaccines and therapeutics to combat this parasitic disease.
Overview of Fasciolopsiasis
Fasciolopsiasis is a neglected tropical disease caused by the intestinal fluke Fasciolopsis buski, a member of the Fasciolidae family of parasites. This zoonotic infection primarily affects humans and pigs in rural and semi-urban areas of Asia, particularly in countries like China, India, and Bangladesh, where poor sanitation and contaminated water sources facilitate the transmission of the parasite.
Fig.1 Life cycle stages of Fasciola hepatica involved in the infection of humans. (Mas-Coma S., et al., 2018)
The life cycle of Fasciolopsis buski involves freshwater snails of the Planorbidae family as intermediate hosts, where the parasite undergoes asexual reproduction. Humans and pigs become infected by ingesting the encysted metacercarial stage of the parasite, typically through the consumption of raw, contaminated aquatic plants or water. Once ingested, the juvenile flukes excyst in the small intestine and mature into adult worms, which can cause significant damage and pathological effects in the host.
Vaccine Development for Fascioliasis
Studies have identified several proteins from F. buski that induce immune responses. For instance, cathepsin L-like proteases have been shown to be potential vaccine candidates due to their crucial role in the parasite's survival and pathogenesis.
Genetic immunization using plasmid DNA encoding for F. buski antigens has demonstrated the potential to induce protective immunity in experimental models. This approach bypasses the need for live attenuated or killed organisms, reducing safety concerns.
Recombinant technology allows for the production of specific F. buski antigens in a controlled environment. These antigens can then be formulated into vaccines that stimulate the host's immune system to recognize and attack the parasite.
Therapeutics Development for Fascioliasis
Praziquantel: This is the first-line therapeutics for fasciolopsiasis. It works by paralyzing the worms, allowing the host's immune system to eliminate them. Research continues on the optimization of praziquantel dosage and frequency to enhance efficacy and reduce side effects.
Nitazoxanide: As an alternative to praziquantel, nitazoxanide has shown efficacy in clearing F. buski infections. It is particularly useful in cases where praziquantel resistance is suspected or observed.
Natural Products: There is a growing interest in the potential of natural products as a source of new anthelmintic compounds. Plant extracts and their metabolites are being studied for their ability to alter the parasite's physiology, providing a novel approach to therapy.
Our Services
Protheragen is at the forefront of developing innovative solutions for the control of fasciolopsiasis. Our services encompass a comprehensive range of vaccine and therapeutic development, tailored to address the unique challenges posed by this disease.
- Fasciolopsis buski Infection Mouse Models
- Fasciolopsis buski Infection Pig Models
- Fasciolopsis buski Infection Rat (Rattus norvegicus) Models
Protheragen's preclinical research services are designed to support the entire spectrum of vaccine and drug development. We offer:
- Immunogenicity Studies: Assessing the immune response to potential vaccine candidates in relevant animal models.
- Pharmacokinetic and Pharmacodynamic Analysis: Determining the behavior of drug candidates within the host to optimize dosing regimens.
- Drug Safety Evaluation: Conducting rigorous testing to ensure that our vaccines and therapeutics meet the highest standards of safety and effectiveness before they advance to clinical trials.
If you are interested in our services, please feel free to contact us.
References
- Mas-Coma S., M. D. Bargues, and M. A. Valero. "Human fascioliasis infection sources, their diversity, incidence factors, analytical methods, and prevention measures." Parasitology 145.13 (2018): 1665-1699.
- Rufino-Moya, Pablo José, et al. "Advancement in Diagnosis, Treatment, and Vaccines against Fasciola hepatica: A Comprehensive Review." Pathogens 13.8 (2024): 669.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
